Future clinical studies should determine whether milatuzumab can indeed restore Fas-signaling and chemotherapy responses in lymphoma, CLL, and potentially other CD74-expressing malignancies. The gene discussed is FAS; the disease is B-cell chronic lymphocytic leukemia.